← Back to 4-AcO-DiPT

4-AcO-DiPT Stats & Data

Psychedelic Research-chemical

Ace Aces 4-ace Ipracetin Iprocetyl 4-acetoxy-dipt 4acodipt

NPS DataHub

MW302.42

FormulaC18H26N2O2

CAS936015-60-0

IUPAC[3-[2-(di(propan-2-yl)amino)ethyl]-1H-indol-4-yl] acetate

SMILESCC(=O)Oc1cccc2ncc(CCN(C(C)C)C(C)C)c12

InChIKeyZPAOVGZYDSXCPK-UHFFFAOYSA-N

2020/5.1 Indol-3-alkylamine; 2021/5.1 Indol-3-alkylamine; 2022/5.1 Indol-3-alkylamine

Chemical Class Tryptamine

Psychoactive Class Psychedelic

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (full)

5-HT2C receptor agonist (full)

History & Culture

4-AcO-DiPT was first characterized in the scientific literature by Alexander Shulgin, with documentation appearing by 2003. The compound is described in TiHKAL (Tryptamines I Have Known and Loved), Shulgin's comprehensive reference work on tryptamine compounds co-authored with Ann Shulgin. The substance represents one of the early psychedelic research chemicals that emerged following Shulgin's initial synthesis and documentation, predating the widespread proliferation of online research chemical vendors that would later characterize the early 2000s market. It was first identified as a novel designer drug in 2005, marking its appearance in recreational and research contexts outside of Shulgin's laboratory work.

Effect Profile

Curated + 47 Reports

Psychedelic 7.2

Strong visuals, auditory effects, and body load with moderate headspace

Visual Intensity×3

1010

Headspace Depth×3

68.5

Auditory Effects×1

1010

Body Load / Somatic Effects×1

1010

Catalog Erowid

Based on reports from:

Erowid Experience Reports PsychonautWiki 4-AcO-DiPT

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Cross-Tolerances

LSD

30% ●○○

Psilocybin

30% ●○○

Psilocin

30% ●○○

Mescaline

30% ●○○

DMT

30% ●○○

5-MeO-DMT

30% ●○○

2C-B

30% ●○○

2C-E

30% ●○○

Experience Report Analysis

Erowid

47 Reports

1999–2012 Date Range

6 With Age Data

28 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 47 experience reports (47 Erowid)

47 Reports

28 Effects Detected

10 Positive

10 Adverse

8 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 10

Empathy 59.6% 70%

Stimulation 57.4% 70%

Music Enhancement 48.9% 70%

Tactile Enhancement 48.9% 70%

Euphoria 42.6% 70%

Color Enhancement 34.0% 70%

Introspection 23.4% 70%

Focus Enhancement 23.4% 70%

Body High 21.3% 70%

Creativity Enhancement 10.6% 70%

Adverse Effects 10

Nausea 38.3% 70%

Anxiety 36.2% 70%

Confusion 29.8% 70%

Muscle Tension 27.7% 70%

Increased Heart Rate 17.0% 70%

Pupil Dilation 14.9% 70%

Headache 10.6% 70%

Motor Impairment 8.5% 70%

Memory Suppression 8.5% 70%

Jaw Clenching 6.4% 70%

Dose-Response Correlation

How effect frequency changes across dose levels

View data table

Effect	Common (n=19)	Strong (n=12)
Visual Distortions	89.5%	75.0%
Empathy	47.4%	66.7%
Stimulation	57.9%	58.3%
Tactile Enhancement	36.8%	58.3%
Music Enhancement	52.6%	25.0%
Anxiety	21.1%	50.0%
Euphoria	42.1%	41.7%
Color Enhancement	36.8%	16.7%
Nausea	36.8%	33.3%
Confusion	31.6%	33.3%
Body High	26.3%	33.3%
Sedation	26.3%	16.7%
Dissociation	26.3%	16.7%
Muscle Tension	26.3%	25.0%
Open-Eye Visuals	10.5%	25.0%

Dose–Effect Mapping

Experience Reports

How reported effects shift across dose tiers, based on 47 experience reports.

Limited tier coverage — most reports fall within the Common / Strong range. Effects at other dose levels may not be represented.

Oral dose range: 20.0–32.0 mg (median 25.0 mg)

Effect	Common (n=19)	Strong (n=12)
visual distortions	90%	75%	↓
empathy	47%	67%	↑
stimulation	58%	58%	→
tactile enhancement	37%	58%	↑
music enhancement	53%	25%	↓
anxiety	21%	50%	↑
euphoria	42%	42%	→
color enhancement	37%	17%	↓
nausea	37%	33%	→
confusion	32%	33%	→
body high	26%	33%	↑
sedation	26%	17%	↓
dissociation	26%	17%	↓
muscle tension	26%	25%	→
open-eye visuals	10%	25%	↑
ego dissolution	21%	—	→
focus enhancement	21%	—	→
increased heart rate	21%	17%	↓
hospital	21%	—	→
auditory effects	21%	—	→

Showing top 20 of 27 effects

Risk Escalation

Sentiment Analysis

Average frequency of positive vs adverse effects across dose tiers

Common n=19

10 positive 35.3% 8 adverse 21.7%

Strong n=12

8 positive 39.6% 7 adverse 27.4%

View effect breakdown

Adverse Effects

Effect	Common (n=19)	Strong (n=12)	Change
Anxiety	21%	50%	+136%
Nausea	37%	33%	-9%
Confusion	32%	33%	5%
Muscle Tension	26%	25%	-4%
Increased Heart Rate	21%	17%	-20%
Headache	10%	17%	+59%
Motor Impairment	—	17%	0%
Pupil Dilation	16%	—	0%
Thought Loops	10%	—	0%

Positive Effects

Effect	Common (n=19)	Strong (n=12)	Change
Empathy	47%	67%	+40%
Stimulation	58%	58%	0%
Tactile Enhancement	37%	58%	+58%
Music Enhancement	53%	25%	-52%
Euphoria	42%	42%	0%
Color Enhancement	37%	17%	-54%
Body High	26%	33%	+26%
Focus Enhancement	21%	—	0%
Introspection	16%	17%	5%
Creativity Enhancement	16%	—	0%

Dosage Distribution

Dose distribution from experience reports

Median: 25.0 mg IQR: 20.0–32.0 mg n=35

Real-World Dose Distribution

62K Doses

From 74 individual dose entries

Oral (n=69)

Median: 20.0mg 25th: 17.0mg 75th: 30.0mg 90th: 37.6mg

mg/kg median: 0.284 mg/kg 75th: 0.408

Common Combinations

Most co-occurring substances in experience reports

Form / Preparation

Most common forms and preparations reported

Body-Weight Dosing

Dose relative to body weight from reports with weight data

Median: 0.365 mg/kg IQR: 0.267–0.427 mg/kg n=34

Redose Patterns

Redosing behavior across 39 reports

25.6% Redosed

1.4 Avg Doses

150m Median Interval

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Denmark	Schedule B	Listed as a Schedule B controlled substance under Danish drug control legislation.
Finland	Controlled substance	Banned in December 2014 under a government regulation that prohibited over 100 psychoactive chemicals.
Germany	Controlled (NpSG)	Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are punishable offenses. Possession is illegal but not subject to criminal penalties.
Japan	Designated Substance (Shitei-Yakubutsu)	Controlled under the Pharmaceutical Affairs Law, making both possession and sale illegal.
Sweden	Illegal	Classified as a health hazard under the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor) as of March 1, 2005, in regulation SFS 2005:26. Both possession and sale are prohibited.
Switzerland	Controlled (Verzeichnis E)	Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
United Kingdom	Class A	Controlled under the Misuse of Drugs Act 1971. This classification applies because 4-AcO-DiPT is an ester of 4-HO-DiPT, which is controlled under the tryptamine catch-all clause.
United States	Unscheduled	Not scheduled under the Controlled Substances Act. However, due to structural similarities to scheduled tryptamines such as psilocin, possession and sale for human consumption may be prosecuted under the Federal Analogue Act. Pending cases have existed since July 2004 involving vendors selling this substance, though no convictions have established further legal precedent.

References

Data Sources

Cited References

← Back to 4-AcO-DiPT